For the Inventor, By the Inventor

Enter assignee name

Seongnam-si, South Korea

Abl Bio Inc.

USPTO Granted Patents = 15

EPO Patents = 3

Trademarks = 2

Forward Citations = 13

Loading Chart...

Loading Chart...

94 inventors (with patents filed for the assignee):

Yangsoon Lee (9 out of 10 patents)

Eunyoung Park (7 out of 7 patents)

Byungje Sung (7 out of 7 patents)

4. Eunsil Sung (7 out of 7 patents)

5. Yeunju Kim (7 out of 7 patents)

6. Hyejin Chung (7 out of 7 patents)

7. Youngdon Pak (6 out of 6 patents)

8. Jinhyung Ahn (5 out of 5 patents)

9. Kyungjin Park (5 out of 5 patents)

10. Donghoon Yeom (5 out of 5 patents)

11. Kyeongsu Park (5 out of 5 patents)

12. Juhee Kim (4 out of 22 patents)

13. Sang Hoon Lee (4 out of 38 patents)

14. Daehae Song (4 out of 4 patents)

15. Yong-Gyu Son (4 out of 4 patents)

15 patents: Sort by Forward Citations

1. 12252541 - Anti-BCMA antibody and use thereof (2025-03-18),

2. 12240913 - Anti-HER2/anti-4-1BB bispecific antibody and use thereof (2025-03-04),

3. 12195538 - Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof (2025-01-14),

4. 12195537 - Anti-4-1BB antibody and use thereof (2025-01-14),

5. 12173070 - Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof (2024-12-24),

6. 12168690 - Anti-EGFR/anti-4-1BB bispecific antibody (2024-12-17),

7. 12122830 - Anti-ROR1 antibody and use thereof (2024-10-22),

8. 12071483 - Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof (2024-08-27),

9. 12049493 - Anti-alpha-synuclein antibodies and uses thereof (2024-07-30),

10. 11891445 - Anti-B7-H3 antibody and use thereof (2024-02-06),

11. 11707533 - Antibody-drug conjugate comprising antibody against human ROR1 and use for the same (2023-07-25),

12. 11261259 - Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof (2022-03-01),

13. 10184010 - Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof (2019-01-22),

14. 10071170 - Antibody-drug conjugate having improved stability and use thereof (2018-09-11),

15. 9598483 - Monoclonal antibody binding specifically to DLL4 and use thereof (2017-03-21),

Abl Bio Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Our team of experts is dedicated to advancing cutting-edge research and bringing new treatments to patients in need. Through our proprietary technology and strategic partnerships, we aim to make a meaningful impact on healthcare and improve outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

15 Patents

#37 in Seongnam-si

#737 in South Korea

#38,730 in the World

Seongnam-si, South Korea

Abl Bio Inc.

Forward Citations = 13

94 inventors:

Yangsoon Lee (9 out of 10 patents)

Eunyoung Park (7 out of 7 patents)

Byungje Sung (7 out of 7 patents)

4. Eunsil Sung (7 out of 7 patents)

5. Yeunju Kim (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…